We will invest $1,000.000.000 in the Russian pharmaceutical industry!
International pharmaceutical companies intend to invest more than $ 1 billion in medicines in Russia
Ilya Dugin, "Farmvestnik" based on the materials of the Thomson Reuters Foundation: Global pharma to pump cash into Russia
Global manufacturers of medicines are ready to invest more than $1 billion in the production of their products in Russia in order to obtain the status of local manufacturers and thus circumvent the stricter requirements imposed by the authorities on imported medicines. A number of them already have production sites in Russia, some have announced real plans, and several more companies have announced their intentions to create production in our country.
Danish Novo Nordisk announced in April this year its intention to invest 80-100 million US dollars in the construction of the plant, which will be the first production enterprise in Russia.
In May of this year, the French pharmaceutical company Sanofi-Aventis received permission to acquire a controlling stake in a Russian insulin manufacturing company.
Nycomed from Switzerland has announced plans to invest 65-75 million euros in the construction of an enterprise for the production of liquid sterile and solid dosage forms in the period up to 2014.
Swedish-British pharmaceutical company AstraZeneca is considering the possibility of manufacturing its main drugs in Russia. The company is already working closely with Russian research centers.
Swiss Novartis said in January that it considers Russia as one of the most attractive developing pharmaceutical markets.
The head of the division for operations in the emerging pharmaceutical markets of the American pharmaceutical company Pfizer announced the company's intention to use the opportunities of these countries more widely, noting that Russia is a priority along with China, Mexico, Turkey, Brazil and India.
Slovenian company KRKA in January this year announced plans to increase the production capacity of its Moscow region enterprise, built in 2003, by 3 times within 3 years. This will be one of the company's largest investments in 2010.
The British GlaxoSmithKline, which is already involved in a joint venture with Russian partners, produces bottling and packaging of vaccines for the prevention of hepatitis. As a representative of GSK recently stated, the company is working on concluding a strategic partnership with the Russian Government.
Hungarian pharmaceutical company Gedeon Richter, which owns an enterprise for the production and packaging of medicines near Moscow, in April this year increased its share in the GC "Protek" from 4 to 5%.
The French pharmaceutical manufacturer Servier in 2007 built a plant for the production of tablet drugs in the Moscow region.
The German pharmaceutical company Stada became the second largest Russian manufacturer of medicines after the acquisition of OAO Nizhpharm in 2005 and CJSC Makiz-Pharma in 2007.
Portal "Eternal youth" http://vechnayamolodost.ru21.06.2010